IpiNovyx Bio is a drug development and platform technology company focused on creating highly-selective, reversible immunoproteasome inhibitors for autoimmune and inflammatory diseases. The company’s proprietary platform enables novel small-molecule inhibitors designed to selectively target the immunoproteasome and modulate specific immune cell types, with preclinical data suggesting a favorable toxicity profile versus conventional immunosuppressive therapies. Preclinical in vivo and in vitro models reported by the company indicate efficacy for modestly selective inhibition and reversible activity, positioning development candidates as potential steroid-sparing and long-term therapies. Proceeds from the announced financing will support advancement of lead candidates toward first-in-human clinical studies, including submission of an investigational new drug (IND) application. The foundational science stems from landmark research at Weill Cornell Medicine and the Hospital for Special Surgery Research Institute, and the technology is in-licensed through Cornell University’s Center for Technology Licensing with medicinal chemistry support from the Tri-Institutional Therapeutics Discovery Institute. IpiNovyx was founded by Orange Grove Bio alongside scientific founders Gang Lin, Carl Nathan, and Franck Barrat.

Total raised

$10M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2021